ConforMIS

ConforMIS, Inc. is a medical technology company, which engages in the development, manufacture, and sale of joint replacement implants. It operates through the following geographical segments: United States, Germany, and Rest of the World. The firm's products include iUni, iDuo, iTotal CR, and iTotal. The company was founded by Philipp Lang in 2004 and is headquartered in Billerica, MA.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cordera™ Hip System with optional patient-specific instrumentation and personalized surgical plan joins the 3D Conformis Hip System as the latest hip technology from Conformis Cordera™ Hip System with optional patient-specific instrumentation and personalized surgical plan joins the 3D Conformis Hip System as the latest hip technology from Conformis

Conformis Announces 510(k) Clearance for Cordera™ Hip System

BILLERICA, Mass., Sept.  24, 2020  (GLOBE NEWSWIRE) -- Conformis, Inc. (Nasdaq: CFMS) today announced it has entered into a definitive agreement with a healthcare focused institutional investor to sell to the investor, in a registered direct offering priced at-the-market under Nasdaq rules, (i) 8,512,088 shares of its common stock and accompanying warrants to purchase up to 8,512,088 shares of common stock and (ii) pre-funded warrants to purchase up to 9,492,953 shares of common stock and accompanying warrants to purchase up to 9,492,953 shares of common stock, for aggregate gross proceeds of approximately $17.25 million.

Conformis, Inc. Announces $17.25 Million Registered Direct Offering Priced At-The-Market

BILLERICA, Mass., Sept.  16, 2020  (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) will participate in the 2020 Oppenheimer Fall Healthcare Life Sciences & MedTech Summit being held September 21-23, 2020 in a virtual format.  Mark Augusti, President and Chief Executive Officer, and Robert Howe, Chief Financial Officer, will represent the Company in a session scheduled to begin at 2:30 pm ET on Tuesday, September 22, 2020.

Conformis, Inc. to Present at the 2020 Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

BILLERICA, Mass., Sept.  08, 2020  (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) will participate in the upcoming 2020 H.C. Wainwright 22nd Annual Global Investment Conference, to be held virtually on September 14-16, 2020.  Mark Augusti, President and Chief Executive Officer, and members of the Company’s management team, will present on Tuesday, September 15, 2020, in a session scheduled to begin at 2:30 p.m. ET.

Conformis, Inc. to Present at the 2020 H.C.

BILLERICA, Mass., Sept.  02, 2020  (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that Mark Augusti, President and Chief Executive Officer, and members of the Company’s executive management team will participate in the 2020 Wells Fargo Virtual Healthcare Conference taking place September 9-10, 2020, in one-on-one meetings.

Conformis, Inc. to Participate in the 2020 Wells Fargo Virtual Healthcare Conference

BILLERICA, Mass., Aug.  20, 2020  (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that it completed the second of three milestones pursuant to the License Agreement and Development Agreement with Howmedica Osteonics Corp., a wholly owned subsidiary of Stryker Corporation also known as Stryker Orthopaedics, under which Conformis is developing patient-specific instrumentation (“PSI”) for use in connection with Stryker’s knee implant offerings. The Company will receive an additional $3.0 million from Stryker for achieving this milestone.

Conformis Announces Achievement of Second Milestone Under Development and License Agreements

BILLERICA, Mass., Aug.  13, 2020  (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that the Company has appointed Farzin Khaghani as its new VP, US Marketing.

Conformis Announces Farzin Khaghani as VP, US Marketing; Inducement Grants Reported

Clinical research published online in July 2020 in The Journal of Bone and Joint Surgery Reviews found that the patients studied, who all received Conformis patient-specific iTotal PS (posterior-stabilized) knee replacement implants, were 90% satisfied, or very satisfied, 18–28 months post-surgery. Clinical research published online in July 2020 in The Journal of Bone and Joint Surgery Reviews found that the patients studied, who all received Conformis patient-specific iTotal PS (posterior-stabilized) knee replacement implants, were 90% satisfied, or very satisfied, 18–28 months post-surgery.

90% Patient Satisfaction Reported in Peer-Reviewed Clinical Study of Conformis iTotal PS Knee Replacements

Conformis' (CFMS) CEO Mark Augusti on Q2 2020 Results - Earnings Call Transcript

BILLERICA, Mass., Aug.  05, 2020  (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today financial results for the second quarter ended June 30, 2020.

Conformis Reports Second Quarter 2020 Financial Results and Announces Planned Portfolio Expansion Targeted at Ambulatory Surgical Centers

ConforMIS (CFMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ConforMIS (CFMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Earnings Call to be Hosted on August 5, 2020

Conformis Reports Preliminary Second Quarter Revenue Results, Amendment to Credit Agreement

Conformis' (CFMS) latest iTotal Identity PS Knee System clears FDA hurdle, paving the way for providing better patient-specific pre-operative surgical plans.

Conformis Next-Generation Identity PS Knee System Gets FDA Nod

iTotal® Identity PS joins iTotal® Identity CR as the latest personalized knee technology from Conformis iTotal® Identity PS joins iTotal® Identity CR as the latest personalized knee technology from Conformis

Conformis Announces 510(k) Clearance for iTotal® Identity PS

Conformis and Zimmer Biomet settled disputes related to Patient-Specific Instrument Patents for Use with Off-the-Shelf Knee, Hip, and Shoulder Implants Conformis and Zimmer Biomet settled disputes related to Patient-Specific Instrument Patents for Use with Off-the-Shelf Knee, Hip, and Shoulder Implants

Conformis Announces Settlement of Patent Dispute

Dr. Malte Asseln awarded annual prize by German Society for Biomedical Engineering at the VDE Association and the Klee Family Foundation for his scientific computer-and-image-based workflow to optimize knee implant design Dr. Malte Asseln awarded annual prize by German Society for Biomedical Engineering at the VDE Association and the Klee Family Foundation for his scientific computer-and-image-based workflow to optimize knee implant design

Prestigious Klee Family Foundation Prize 2020 Awarded for Outstanding Scientific Work Identifying Patient-Specific Approach as Better Way to Optimize Knee Implant Design

Conformis (CFMS) CEO Mark Augusti on Q1 2020 Results - Earnings Call Transcript

ConforMIS (CFMS) delivered earnings and revenue surprises of -55.56% and -13.04%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

ConforMIS (CFMS) Reports Q1 Loss, Lags Revenue Estimates

ConforMIS (CFMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ConforMIS (CFMS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

BILLERICA, Mass., April  20, 2020  (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) today announced that on April 17, 2020 the Company entered into a $4,719,800 promissory note with East West Bank (NASDAQ:EWBC) under the Paycheck Protection Program (“PPP”) offered by the U.S. Small Business Administration (the "SBA") to mitigate the negative financial and operational impacts of the coronavirus (COVID-19) pandemic.  In response to the coronavirus (COVID-19) pandemic, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) authorizes the SBA to make available low-interest rate loans to qualified small businesses under the PPP.  According to the terms of the PPP, all or a portion of the loan may be fully forgiven if the funds are used for payroll costs (and at least 75% of the forgiven amount must have been used for payroll), interest on certain other outstanding debt, rent, and utilities.

Conformis Receives $4.7 Million under the Paycheck Protection Program

Conformis Announces Actions to Mitigate COVID-19 Impact

Kirkland Lake Gold

Lonestar Resources US

Novan

Uranium Energy

Inside the top-ranked stocks that have been exhibiting rising P/E ratios.

Buy 5 Top-Ranked Stocks With Rising P/E

Conformis, Inc. (CFMS) CEO Mark Augusti on Q4 2019 Results - Earnings Call Transcript

ConforMIS (CFMS) delivered earnings and revenue surprises of 20.00% and -0.09%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

ConforMIS (CFMS) Reports Q4 Loss, Lags Revenue Estimates

Rating Highlights Positive Five-Year Survivorship Following Total Knee Arthroplasty Rating Highlights Positive Five-Year Survivorship Following Total Knee Arthroplasty

News for ConforMIS Stock (CFMS)